Editas Medicine (EDIT) Change in Receivables (2015 - 2025)
Editas Medicine (EDIT) posted quarterly Change in Receivables of $7.5 million for Q3 2025, up 6491.53% year-over-year from $114419.6 in Q3 2024, and up 9569.23% quarter-over-quarter from $78000.0 in Q2 2025.
Powered by 
Analysis
Editas Medicine (EDIT) Change in Receivables (2015 - 2025) Analysis & Trends
Editas Medicine (EDIT) has reported Change in Receivables for 11 consecutive years, with $7.5 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Change in Receivables rose 6491.53% year-over-year to $7.5 million; the TTM figure through Sep 2025 stood at $8.0 million (up 448.61% YoY), while the FY2024 annual figure was $6.1 million, up 20.57% from the prior year.
- Change in Receivables advanced to $7.5 million in Q3 2025 per EDIT's latest filing, from $78000.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $16.1 million in Q4 2024 and bottomed at -$15.8 million in Q1 2025.
- Historically, Change in Receivables has averaged $109578.9 across 5 years, with a median of -$1000.0 in 2024.
- Annual changes were most pronounced in 2021 — Change in Receivables sank 1133.33% — and 2022, when it surged 31306.25%.
- Editas Medicine's Change in Receivables stood at $16000.0 in 2021, then soared by 31306.25% to $5.0 million in 2022, then soared by 54.53% to $7.8 million in 2023, then surged by 107.86% to $16.1 million in 2024, then slumped by 53.27% to $7.5 million in 2025.
- Business Quant data shows EDIT's Change in Receivables at $7.5 million in Q3 2025, $78000.0 in Q2 2025, and -$15.8 million in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -53.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 117.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 31.60 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Editas Medicine | 287.84 Mn | 141.19 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | 7.54 Mn |
| Jun 30, 2025 | 78,000.00 |
| Mar 31, 2025 | -15.76 Mn |
| Dec 31, 2024 | 16.14 Mn |
| Sep 30, 2024 | -118,000.00 |
| Jun 30, 2024 | -1,000.00 |
| Mar 31, 2024 | -9.94 Mn |
| Dec 31, 2023 | 7.77 Mn |
| Sep 30, 2023 | 136,000.00 |
| Jun 30, 2023 | 2.04 Mn |
| Mar 31, 2023 | -4.90 Mn |
| Dec 31, 2022 | 5.03 Mn |
| Sep 30, 2022 | -593,000.00 |
| Jun 30, 2022 | -659,000.00 |
| Mar 31, 2022 | 1.11 Mn |
| Dec 31, 2021 | 16,000.00 |
| Sep 30, 2021 | -80,000.00 |
| Jun 30, 2021 | -341,000.00 |
| Mar 31, 2021 | -5.38 Mn |
| Dec 31, 2020 | 4.99 Mn |